Christopher Richard Anzalone - 02 Jan 2026 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ARWR
Reported as of: 02 Jan 2026
Net transaction value: -$871,703
SEC form: 4
Accepted by SEC: 05 Jan 2026, 21:39:41 UTC
Prior SEC filing: 30 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/Christopher Anzalone

Key filing fact

Christopher Richard Anzalone filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 05 Jan 2026.

Key facts

This page summarizes Christopher Richard Anzalone's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2026, 21:39.

Change

Previous filing in this sequence was filed on 30 Dec 2025.
Current net transaction value: -$871,703.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001423029 Primary reporting owner

Anzalone Christopher Richard

Relationship: Chief Executive Officer, Director
Address: 177 E. COLORADO BLVD, SUITE 700, PASADENA
Signature: /s/Christopher Anzalone
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARWR transaction

Common Stock

Sale

Transaction value: $488,566
Shares: -7,416
Change %: -0.19%
Price: $65.88
Shares after: 3,798,510
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

ARWR transaction

Common Stock

Sale

Transaction value: $383,137
Shares: -5,771
Change %: -0.15%
Price: $66.39
Shares after: 3,792,739
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Footnote F2

Partial disposition of shares to satisfy tax withholding obligations.

Footnote F3

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.28 to $66.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F4

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Footnote F5

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.